We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Medica 2024 Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Nanomaterial-Based Diagnostic Technology Accurately Monitors Drug Therapy in Epilepsy Patients

By LabMedica International staff writers
Posted on 13 Nov 2024

Many patients with epilepsy take anti-epileptic drugs to control frequent seizures in their daily lives. To optimize treatment and avoid side effects from overdosing, it is crucial for patients to regularly monitor the concentration of these drugs in their bodies. However, the current diagnostic technologies used in hospitals for this purpose face challenges in terms of both accuracy and time efficiency. The most widely used method, immunoassay, is prone to cross-reactions with similar drugs, which lowers diagnostic accuracy. While mass spectrometry, which ionizes samples using electrospray, offers greater accuracy, it is time-consuming and expensive, creating additional burdens for patients. To address these limitations, researchers have developed a novel diagnostic and treatment system based on nanomaterials for therapeutic drug monitoring (TDM) in epilepsy patients. This approach promises to significantly reduce the time and cost of current diagnostics while maintaining accuracy, ultimately easing the burden on patients managing their condition.

This innovative nanomaterial-based diagnostic method was developed by scientists at the Korea Research Institute of Standards and Science (KRISS, Daejeon, South Korea), in collaboration with domestic university hospitals. By incorporating a mixture of molybdenum ditelluride (MoTe2) and tungsten ditelluride (WTe2) nanosheets into the sample and ionizing it with a laser, the researchers were able to enhance both the speed and sensitivity of drug detection. When applied to samples from 120 epilepsy patients, the technology demonstrated over 99.9% reliability, while reducing the analysis time to just one-sixteenth of the original. Furthermore, the number of samples that could be analyzed in a single session increased more than tenfold, potentially cutting diagnostic costs by half.


Image: Schematic diagram of nanomaterial-based anti-epileptic drug concentration diagnostic technology (Photo courtesy of KRISS)
Image: Schematic diagram of nanomaterial-based anti-epileptic drug concentration diagnostic technology (Photo courtesy of KRISS)

Related Links:
KRISS


New
Gold Member
Syphilis Screening Test
VDRL Antigen MR
Antipsychotic TDM AssaysSaladax Antipsychotic Assays
New
Nuclear Matrix Protein 22 Test
NMP22 Test
New
Liquid Based Cytology Production Machine
LBP-4032

Latest Technology News

Optical Biosensor Rapidly Detects Monkeypox Virus at Point of Care

New Noninvasive Methods Detect Lead Exposure Faster, Easier and More Accurately at POC

Noninvasive Test Detects Malaria Without Blood Sample